Brenus Pharma is a french innovative biotech aiming to become leader in allogenic cellular immunotherapy thanks to its unique, patented and scalable technology Stimulated Tumor Cells (STC). Its first therapeutic candidate STC-1010 shows a significant improvement in overall survival in an animal model of colorectal cancer. STC-1010 stimulates patients immune system by fighting immunotolerance, chemoresistance, and the harmful tumor micro-environment which are the three causes of treatment failure. STC-1010 has a rational for use alone and in combination with chemotherapy and immune-checkpoint inhibitors. Brenus Pharma is exploring other indications for STC-1010 and will develop other candidates through its STC platform.